What phenotypic changes are seen with endothelin-1 (ET-1) treatment in cardiomyocytes?

What phenotypic changes are seen with endothelin-1 (ET-1) treatment in cardiomyocytes?


If you opened this Solution from a search, your last search results are still available in a separate tab. Click the button below to begin a new search.

SEARCH ALL SOLUTIONS

Still Have Questions?
If you did not find an answer to your question, please contact us to speak with an expert:

(877) 320-6688 (toll-free)
+1 (608) 310-5100
or submit a support request

Carlson et al. (2013) described methods to evaluate the phenotypic change in iCell® Cardiomyocytes cell size in response to ET-1 treatment. These methods include staining actin with phalloidin and evaluating the cell size using image analysis software. Our Application Protocol also provides basic guidelines for immunofluorescent staining using sarcomeric alpha-actinin (ACTN2).

References:

  1. Application Protocol: Immunofluorescent Labeling
  2. Carlson et al (2013) Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy.